Teva settling suits for $285 million; FDA allows India cancer drug import to ease shortage;

> Teva Pharmaceuticals ($TEVA) is discovering that size matters. The Israeli generics giant reportedly is setting aside $285 million to settle lawsuits alleging that the jumbo-sized vials it used for its anesthetic propofol encouraged re-use and led to colonoscopy patients developing hepatitis C. Story

> The FDA is temporarily allowing Lipodox, from Sun Pharma, to be imported from India to ease the shortage of Doxil. A Sun Pharma spokeswoman said in email to FiercePharmaManufacturing, "we've been selling Lipodox in India, and in the past have said that we would possibly seek to file an ANDA with the USFDA." Release

> Valeant Pharmaceuticals ($VRX) has agreed to sell the manufacturing and marketing rights to drug products that treat acne and actinic keratosis, a pre-cancerous skin lesion, to Mylan Pharmaceuticals ($MYL) and marketing rights to a drug that treats fine line wrinkles to Spear Pharmaceuticals in order to get FTC approval to acquire Ortho Dermatologics from Johnson & Johnson ($JNJ) and Dermik Laboratories from Sanofi ($SNY). FTC release

> Sanofi ($SNY) will close its Genzyme R&D hub in Cambridge, U.K., by year end in its continuing effort to cut nearly $3 billion from expenses. Story

> Regulators' efforts to track down an Egyptian company that reportedly sold fake Avastin into the approval supply chain have so far ended in a dead end. Story

> The FDA has issued a warning letter to Winnipeg, Canada-based Intelligent Hospital Systems for shortcomings in the manufacturing and complaint processes for its robotic intravenous automation, or RIVA, system, a self-contained unit used in hospitals for filling IV syringes and bags. FDA warning letter